CD26 mRNA Expression Level In Systemic lupus Erythematosus Patients Attending Benha University Hospital

Background : CD26 has a role in the pathogenesis of inflammation and participates in degrading interferon-γ-induced chemokine and inflammatory cytokines which have a role in Systemic lupus Erythematosus (SLE) pathogenesis. Objectives: This work was carried out to evaluate the level of CD26 mRNA expression in the peripheral blood leucocytes of SLE patients by quantitative RT-PCR and correlates this level with the disease activity and lupus nephritis. Methodology: thirty SLE patients' blood samples were obtained, leucocytes were isolated and the level of CD26 mRNA expression was evaluated by RT-PCR. Twenty healthy subjects matched for age and sex were chosen as a control group. All cases were subjected to full history taking, thorough clinical exanimation and laboratory investigations. The disease activity was evaluated with systemic lupus erythematosus disease activity index (SLEDAI).. Patients were subdivided into: 12 SLE patients with lupus nephritis and 18 SLE patients without lupus nephritis. Results : CD26 mRNA expression increased 1.28 fold in SLE patients compared to the controls (p<0.05) with no significant correlation between CD26 mRNA expression and SLEDAI score. No significant difference (p>0.05) was found among patients with and those without lupus nephritis. Conclusion : Our results support the hypothesis that CD26 mRNA plays a role in the pathogenesis of SLE; however it is not a good predictor of SLE disease activity or lupus nephritis.

[1]  Xiangli Zhao,et al.  Delayed allogeneic skin graft rejection in CD26-deficient mice , 2018, Cellular & Molecular Immunology.

[2]  D. Tarlinton,et al.  Lyn, Lupus, and (B) Lymphocytes, a Lesson on the Critical Balance of Kinase Signaling in Immunity , 2018, Front. Immunol..

[3]  A. Ahmadzadeh,et al.  CD 26 mRNA expression in Systemic Lupus Erythematosus , 2018 .

[4]  C. Klemann,et al.  Cut to the chase: a review of CD26/dipeptidyl peptidase‐4's (DPP4) entanglement in the immune system , 2016, Clinical and experimental immunology.

[5]  Grainne Murphy,et al.  Effect of gender on clinical presentation in systemic lupus erythematosus. , 2013, Rheumatology.

[6]  Gerald McGwin,et al.  Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. , 2012, Arthritis and rheumatism.

[7]  K. Hara,et al.  Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. , 2012, Translational research : the journal of laboratory and clinical medicine.

[8]  C. Lam,et al.  Decreased Expression of T Lymphocyte Co-Stimulatory Molecule CD26 on Invariant Natural Killer T Cells in Systemic Lupus Erythematosus , 2009, Immunological investigations.

[9]  A. Braun,et al.  CD26 (dipeptidyl‐peptidase IV)‐dependent recruitment of T cells in a rat asthma model , 2005, Clinical and experimental immunology.

[10]  T. Mimori,et al.  Reduction of serum soluble CD26/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus. , 2002, The Journal of rheumatology.

[11]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[12]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[13]  T. Nagatsu,et al.  Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in mice with lupus erythematosus-like syndrome and in patients with lupus erythematosus and rheumatoid arthritis. , 1987, Clinical chemistry.